Soft Q2 + guidance downgrade
26/09/22 -"Considering the recent shift in US patient/consumer spending patterns i.e. delayed purchases – which could also impact other (mature) markets, worsening supply chain concerns and high cost inflation, ..."
Pages
58
Language
English
Published on
26/09/22
You may also be interested by these reports :
16/04/24
Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the ...
15/04/24
The FY23 reported EPS came in ahead of our expectations, as the firm more than offset the H2 23 wage inflation with very strong profit margin ...
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
09/04/24
bioMerieux has reported better-than-expected Q1 organic sales growth, with healthy growth visible across both segments. Besides this, a promising ...